Enhui Yao

Enhui Yao


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
TRTong Ren
Tong Ren
AMAng Ma
Ang Ma
RZRengong Zhuo
Rengong Zhuo
HZHuaying Zhang
Huaying Zhang
LPLu Peng
Lu Peng
LYLichao Yang
Lichao Yang
Oleoylethanolamide (OEA) is an endogenous peroxisome proliferator-activated receptor α (PPARα) agonist that acts on the peripheral control of energy metabolism. However, its therapeutic potential and related mechanisms in hepatic glucose metabolism under type 2 diabetes mellitus (T2DM) are not clear. Here, OEA treatment markedly improved glucose homeostasis in a PPARα-independent manner. OEA efficiently promoted glycogen synthesis and suppressed gluconeogenesis in mouse primary hepatocytes and liver tissue. OEA enhanced hepatic glycogen synthesis and inhibited gluconeogenesis via LKB1/AMPK signalling pathways. PPARα was not involved in the roles of OEA in the LKB1/AMPK pathways. We found that OEA exerts its anti-diabetic effect by increasing glycogenesis and decreasing gluconeogenesis via the LKB1/AMPK pathway. The ability of OEA to control hepatic LKB1/ AMPK pathways may serve as a novel therapeutic approach for the treatment of T2DM. SIGNIFICANCE STATEMENT 1. OEA exerted a potent anti-hyperglycaemic effect in a PPARα-independent manner; 2. OEA played an anti-hyperglycaemic role primarily via regulation of hepatic glycogen synthesis and gluconeogenesis; 3. The main molecular mechanism of OEA in regulating liver glycometabolism is activation of the LKB1/AMPK signalling pathway.

14 November 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
EYEnhui Yao
Enhui Yao
LLLili Luo
Lili Luo
CLChenxi Lin
Chenxi Lin
JWJing Wen
Jing Wen
YLYanglongfei Li
Yanglongfei Li
XJXin Jin
Xin Jin
Reperfusion therapy after myocardial infarction may lead to myocardial injury, which can be complicated and exacerbated by diabetes. The existing therapeutic methods for myocardial ischemia-reperfusion injury (MIRI) in diabetic patients are not ideal. Oleoylethanolamide (OEA) has been found to have protective effects on diabetes and acute cerebral ischemia. This study aimed to determine whether OEA can alleviate MIRI in diabetic rats, and to explore the underlying mechanism. The model of diabetic rats with MIRI was established by blocking the left coronary artery for 30 min, followed by restoring blood flow stability for 120 min. The myocardial enzyme spectrum, area of MIRI, and expression levels of apoptosis-related proteins were detected. The results showed that OEA pretreatment could reduce myocardial infarction area, protect myocardial tissue structure, and reduce myocardial cell apoptosis in diabetic rats with MIRI. Meanwhile, the levels of creatine kinase (CK)-MB (CK-MB), lactate dehydrogenase (LDH), and malondialdehyde (MDA) were reduced, while superoxide dismutase (SOD) level was elevated. H9C2 cells were treated with high glucose and oxygen-glucose deprivation/reperfusion (OGD/R) to establish an in vitro model. Capsazepine (CPZ), an antagonist of transient receptor potential vanilloid subtype 1 (TRPV1), and LY294002, an inhibitor of PI3K, were used to treat H9C2 cells in vitro. Apoptosis level and the expression levels of apoptosis-related proteins were measured. It was found that OEA activated TRPV1 and the PI3K/Akt signaling pathway, downregulated the expression levels of apoptosis-related proteins (Bcl-2 and cleaved caspase-3), and ameliorated the apoptosis of H9C2 cells treated with high glucose and OGD/R. This study clarified that OEA, as a TRPV1 agonist, could reduce myocardial cell apoptosis by activating the PI3K/Akt signaling pathway in diabetic rats with MIRI. The findings may provide a theoretical basis for administration of OEA as a potential therapeutic agent into diabetic patients with MIRI.

10 December 2025 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
CLChaoyang Lin
Chaoyang Lin
QLQianyao Lai
Qianyao Lai
EFEnze Fang
Enze Fang
BLBen Luo
Ben Luo
ZCZhiwei Chen
Zhiwei Chen
EYEnhui Yao
Enhui Yao

7 March 2026 in Journal of Cardiovascular Magnetic Resonance
Verified
Journal Article
Open access
CLChaoyang Lin
Chaoyang Lin
YYYixin Yang
Yixin Yang
QLQianyao Lai
Qianyao Lai
JCJiahui Chen
Jiahui Chen
EWEnhao Wei
Enhao Wei
EYEnhui Yao
Enhui Yao
Ventricular-arterial coupling (VAC) is fundamental to cardiovascular efficiency, but its value for predicting cardiovascular disease (CVD) in the general population is unclear. This study aimed to evaluate the predictive value of three novel non-invasive VAC parameters-the ratio of arterial stiffness index to global longitudinal strain (ASI/GLS), estimated pulse wave velocity to GLS (ePWV/GLS), and left ventricular end-systolic volume to stroke volume (LVESV/LVSV)-for incident atrial fibrillation (AF), stroke, heart failure (HF), coronary heart disease (CHD), all-cause and CVD mortality. We analyzed UK Biobank participants free of baseline significant structural CVD or prior major cardiac surgery. VAC parameters were derived from arterial stiffness metrics and cardiac magnetic resonance (CMR). Associations were assessed using multivariable Cox or Fine-Gray models with false discovery rate (FDR) correction. Incremental prognostic value was evaluated using likelihood ratio tests, C-indices, and continuous net reclassification improvement (NRI). The study included 38,144 participants (mean age 63.5 ± 7.5 years; 47.2% men) with a median follow-up of 4.82 years. After adjustment for clinical features, all three VAC parameters were associated with increased risk of AF, stroke, HF, CHD, all-cause and CVD mortality (except ASI/GLS for CHD). For incident HF, the addition of VAC parameters yielded substantial incremental value, raising C-indices to 0.789-0.835 with NRIs of 11.0%-24.1%. Beyond some respective conventional CMR indices, all three VAC parameters remained independent predictors for incident stroke, whereas ePWV/GLS was specifically independent for incident AF (hazard ratio [HR] 1.19, 95% confidence interval [CI] 1.10-1.29), HF (HR 1.26, 95% CI 1.11-1.43), and CHD (HR 1.11, 95% CI 1.001-1.23). Furthermore, while VAC parameters were independently associated with all-cause mortality regardless of LVEF, their associations with CVD mortality were largely attenuated by LVEF. In the general population, non-invasive VAC parameters predict various adverse cardiovascular outcomes. Incorporating ASI/GLS or ePWV/GLS into traditional risk assessment enhances prognostic value in specific clinical scenarios.

26 September 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
WLWentao Li
Wentao Li
PMPeiyao Ma
Peiyao Ma
YHYi Huang
Yi Huang
YGYinghui Ge
Yinghui Ge
QLQing Lin
Qing Lin
EYEnhui Yao
Enhui Yao
This study aimed to investigate the association between coronary tortuosity (CoTo) and hypertrophic cardiomyopathy (HCM) and to evaluate its potential prognostic value. A total of 195 patients with HCM and a matched non-HCM cohort were enrolled. The prevalence of CoTo was significantly higher in HCM group than in non-HCM controls (63.6% versus 37.9%, P < 0.001). Multivariate logistic regression demonstrated that HCM was independently associated with a 3-fold increased odds of CoTo (OR 3.02, 95% CI 1.97–4.61, P < 0.001). During a mean follow-up of 2.57 ± 1.2 years, HCM patients with CoTo experienced worse primary outcomes than those without CoTo (RR 2.39, 95% CI 1.03–5.54, P = 0.031), and each 1-point increase in the CoTo score was associated with a 51% higher hazard of the primary outcomes (HR 1.51, 95% CI 1.27–1.80, P < 0.001). In a subgroup of 62 patients who underwent cardiovascular magnetic resonance strain analysis, basal global longitudinal displacement (GLD) was significantly lower in the CoTo group (5.11 ± 0.95 versus 5.90 ± 1.20, P = 0.007) and was independently and inversely associated with CoTo (OR 0.69, 95% CI 0.49–0.97, P = 0.032). In conclusion, patients with HCM are more susceptible to CoTo, which is associated with an elevated risk of adverse events, and CoTo correlates with reduced basal myocardial longitudinal motion.

29 October 2026 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
TRTong Ren
Tong Ren
SYShengnan Yu
Shengnan Yu
XJXilin Jiang
Xilin Jiang
JWJing Wen
Jing Wen
CYChangsheng Yan
Changsheng Yan
LYLichao Yang
Lichao Yang
BACKGROUND: Atherosclerosis is frequently associated with both an increased incidence and accelerated development of cancer. However, the impact of atherosclerosis progression on the efficacy of tumor surveillance by cytotoxic immune cells, particularly natural killer (NK) cells, remains poorly understood. This study aims to explore how atherosclerosis affects NK cell–mediated tumor surveillance in both animal models and humans. METHODS: We analyzed peripheral blood NK cells from patients with atherosclerosis with early-stage (<50% stenosis) versus advanced-stage (≥50% stenosis) coronary artery lesions by flow cytometry to assess NK cell frequency, PPARα (peroxisome proliferator–activated receptor alpha) expression, and IFN-γ (interferon gamma) production. In parallel, we used atherosclerotic plaque progression and regression models, including high-fat diet-fed Apo –/– mice and aortic arch transplantation into wild-type, Apoe –/– , Rag1 –/– , and NK cell–specific PPARα knockout ( Ppara flox/flox Ncr1 Cre/+ ) mice. NK cell phenotype and function were evaluated by flow cytometry for immune checkpoint molecules (PD-1 [programmed cell death protein-1], TIM-3 [T-cell immunoglobulin and mucin-domain containing-3], LAG-3 [lymphocyte activation gene-3], and TIGIT [T-cell immunoglobulin and ITIM domain]) and effector cytokines (IFN-γ, GZMB [granzyme B]). Antitumor capacity was assessed in B16F10 melanoma and ID8 ovarian cancer models in atherosclerosis mice, with or without a PPARα agonist (oleoylethanolamide) or an mTOR (mechanistic target of rapamycin kinase) agonist (MHY1485) treatment. Mechanistic studies included immunoblotting for mTOR pathway components and transcriptomic correlation analyses (GSE94044, GSE24495). RESULTS: We found that atherosclerotic plaques induced PPARα deficiency in NK cells, which impaired their cytotoxicity and weakened tumor immunosurveillance. Mechanistically, PPARα-deficient NK cells exhibited elevated immune checkpoint expression, an exhaustion phenotype, and markedly diminished mTOR signaling. Administration of the PPARα agonist oleoylethanolamide restored NK cell effector function and enhanced tumor-killing efficacy in vivo, whereas mTOR agonism partially rescued the defect caused by PPARα loss. These findings underscore the suppressive effects of arterial plaques on NK cell–mediated antitumor immunity and suggest PPARα compensation as a potential immunotherapeutic strategy. CONCLUSIONS: Our study unveils a novel association between atherosclerosis and the attenuation of NK cell antitumor immunity. Specifically, plaque-induced downregulation of PPARα in NK cells leads to uncontrolled immune checkpoint expression, causing NK cell exhaustion and diminished antitumor function. Pharmacological enhancement of PPARα signaling rejuvenated NK cell activity and reduced tumor growth in atherosclerosis. Therefore, targeting PPARα offers a promising therapeutic approach for cancer treatment and prevention in individuals with atherosclerosis.